Eighteen percent more calories burned. No change in food intake. No extra exercise. That’s what UC Berkeley researchers reported when they gave obese male mice an oral compound called TOFA — and watched the fat disappear while the muscle stayed. The study, published in Science Advances on August 21, 2026, matters because it targets a problem that haunts current weight-loss drugs: GLP-1 drugs shrink your appetite brilliantly, and sometimes take your muscle along for the ride. TOFA works from the opposite direction. This is mice-only data — full stop — but the mechanism is worth understanding.
What TOFA Actually Does
Two switches, opposite directions, one molecule — and that combination appears to be the whole point
Most obesity drugs suppress appetite. TOFA takes a different route: it blocks ACC1 and ACC2 — the enzymes that build new fat from scratch — while simultaneously activating PPARα and PPARδ, molecular switches that flip cells into fat-burning mode. Think of it as shutting down the production line while cranking up the furnace. Researchers tried combining a separate ACC inhibitor with a PPAR activator to replicate the effect. It didn’t work as well. Having both actions inside a single molecule appears to matter in ways the team doesn’t yet fully understand.
Obese male mice lost roughly 18% of body weight over four weeks. Food intake, physical activity, and body temperature didn’t move. Nearly all the lost weight came from fat mass — lean mass held statistically steady. The authors are clear on why: because the mice kept eating normally, their bodies had sufficient nutrients to maintain muscle while TOFA redirected metabolism toward burning fat. The drug didn’t protect muscle. It just never starved it
The Ozempic Question
Early mouse data suggests TOFA may complement GLP-1 drugs rather than simply replace them
“Significantly allerelated diseases without affecting food intake or muscle mass.” — Study authors, Science Advances
GLP-1 drugs like semaglutide and tirzepatide work — until you stop, and appetite often rebounds. In mouse experiments, TOFA to obese mice combined with either drug produced greater fat loss and better metabolic results than either treatment alone, an effect the paper describes as more than additive. When TOFA-treated mice stopped treatment, they also maintained lower weight longer than semaglutide-treated mice, whose food intake and weight rebounded quickly. Beyond weight, TOFA improved:
- fasting glucose
- insulin sensitivity
- cholesterol
- triglycerides
- fatty liver markers
across more than 20 mouse experiments
Worth flagging clearly: lead researcher Anders Näär and two co-authors co-founded ReRx Therapeutics, which is developing TOFA as ReRx-001. That’s a disclosed conflict of interest. The science may be solid — but the people running it have financial skin in the game
Pump the Brakes
Before you start Googling pharmacy availability, here’s what the data actually supports — and what it doesn’t
Every experiment used male mice only. Sex differences in metabolism are significant, and female outcomes are completely unknown. TOFA has never been tested in humans. Minimum effective doses, long-term safety, and off-target effects remain uncharacterized. Rat and larger-animal toxicology studies are the mandatory next step before any human trials can begin
TOFA resurrects an approach the field largely set aside — raising energy expenditure rather than suppressing appetite — and offers early evidence it might spare muscle in the process. That’s genuinely worth watching. Whether it survives contact with human biology is the only question that actually matters
